Modafinil: the unique properties of a new stimulant.

Lyons TJ, French J

Headquarters USAF Human Systems Division,
 Brooks Air Force Base, TX 78235.
Aviat Space Environ Med 1991 May;62(5):432-5

ABSTRACT

Modafinil, a novel stimulant which has several remarkable features that distinguish it from other stimulants, has been developed by Lafon, a French pharmaceutical company. Unlike the amphetamines, for example, modafinil is reported to have minimal peripheral side effects at therapeutic doses. It also appears to have a low abuse potential, does not interfere with normal sleep, and does not seem to produce tolerance. It improves vigilance especially in sleep-deprived subjects. It has been used clinically for up to 3 years in the treatment of narcolepsy and idiopathic hypersomnia. It could be an ideal replacement for amphetamine in short-term operations in which fatigue might threaten the successful completion of a mission. We recommend that military laboratories experienced in studying sustained performance include modafinil or perhaps a more selective alpha 1 receptor agonist in their investigations.

Back                          to order

Modafinil research

 1.   Modafinil  for sustaining the alertness of helicopter pilots
 2.   Modafinil  augmentation of antidepressant treatment
 3.   Modafinil  the unique properties of a new stimulant 
 4.   Modafinil  children with attention-deficit/hyperactivity disorder
 5.   Modafinil  tolerability in healthy male volunteers
 6.   Modafinil  successful treatment of hypersomnia & narcolepsy
 7.   Modafinil  narcolepsy: symptoms and management
 8.   Modafinil  amplification of cortical serotonin release
 9.   Modafinil  treatment of alcoholic organic brain syndrome
10.  Modafinil  effect on melatonin, cortisol, and growth hormone
11.  Modafinil  in obstructive sleep apnea-hypopnea syndrome